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evaluations is typically not long lasting. We investigated the
major factors affecting the “expiration date” of economic evalu-
ations using conjugate meningococcal vaccination strategies as
case example. METHODS: In March 2007, we conducted a
systematic literature review of journal articles, based on a
comprehensive key-word based search in generic (PUBMED,
EMBASE) and specialized electronic databases (HEED, NHS
EED), accompanied by manual searches of speciﬁc journals. The
applied methodology in the identiﬁed studies was compared
and matched to the respective national guidelines for economic
evaluation. The current external validity of the study results
and possible adjustments for its improvement were examined.
RESULTS: A total of six published economic evaluations of
conjugate meningococcal vaccination strategies were found.
Overall, they showed that the investigated vaccination strategies
were cost-effective, especially the ones targeting children at
approximately age 1. Adherence of the evaluations to the respec-
tive guidelines was high except for the discount rate. The latter
was however directly related to the recent change in Dutch and
UK recommendations. Sensitivity analysis was available for
many factors, inclusive the discount rate allowing the estimation
of the impact of those recent changes. Similarly, the effect of new
ﬁndings about the vaccination protection duration and herd
immunity could also be estimated for those evaluations that
included those factors in their sensitivity analysis. These were
however scarce. CONCLUSION: An extensive sensitivity analy-
sis for all important factors that might change over time can
extend the expiration date of economic evaluations. Ultimately,
user-friendly and highly ﬂexible models available on the internet
might be the best way to transfer study results over time.
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OBJECTIVES: The purpose of this study was to validate cross-
sectionally the MINI-HIV questionnaire in HIV patients treated
with saquinavir in Spanish hospitals. METHODS: Cross-
sectional observational post-launch and multicentre study. HIV
Patients over 18 years, who were under HAART with Saquinavir.
One visit was carried out. Socio-demographic and clinical vari-
ables (symptoms, time since HIV diagnosis, CDC stage, CD4 and
viral load), treatment adherence (GEEMA questionnaire), a ques-
tion about general health status and the speciﬁc QoL question-
naire Mini-HIV (0 = better QoL; 100 = worse Qol) were
collected. RESULTS: A total of 948 patients were included.
Mean age (SD) was 42 (8.62) years. Mean (SD) time since diag-
nosis was 11.3 (5.6). A total of 36.1% were in Stage C of CDC.
Mean score (SD) obtained in Mini-HIV was of 30.2 (17.8). A
total of 64.9% had bad Qol (cut of point under 22 score).
Correlation between Mini-HIV score and CD4 was low (-0.134)
although it was signiﬁcant (p < 0.01). In patients with detectable
viral load mean (SD) of MINI-HIV score was lower than in
patients with undetectable viral load (32.9 (18.1) vs. 28.8 (17.5);
p < 0.01). QoL was worse in patients who presented symptoms
in the last two weeks or that presented other concomitant disease
(p < 0.01). The more frequent symptoms were weakness, anxiety,
insomnia and depression. There was no difference in MINI-HIV
score according to the form of administration (BID vs OD).
Internal consistency of MINI-HIV was of 0.914 (higher than 0.7
theoretical). General health status was ‘very good’ in 42.3% of
the patients. MINI-HIV scores were related to the general health
status question (p < 0.01). Non adherent patients obtained
higher scores (worse Qol) than adherent patients (p < 0.01).
CONCLUSION: The results of this study show that Mini-HIV
has good psychometrical properties and can be a good tool for
monitoring treatment effectiveness and health states of HIV
patients.
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OBJECTIVES: To develop and validate a self-administered ques-
tionnaire assessing subjects’ perception and experience with
injection, and their acceptance of injection site reactions (ISR)
including pain following inﬂuenza vaccination. METHODS: Fol-
lowing a literature review, the VAPI questionnaire was simulta-
neously developed in US English, German and French, based on
interviews of subjects (n = 33) vaccinated intramuscularly (IM)
or intradermally (ID) with an inﬂuenza vaccine. Items were
generated from subjects’ verbatim, comprehension tested with
elderly and adult vaccinees (n = 23); then a linguistic validation
was done. The initial, 44 item-version of the questionnaire was
administered 21 days after vaccination to subjects from Belgium,
France, Spain, the UK, Germany and Italy who were participat-
ing in clinical trials comparing ID versus IM inﬂuenza vaccina-
tion.Scale construction and item reduction were conducted using
principal component and multitrait analyses with 549 English
subjects. Psychometric validation of the ﬁnal questionnaire was
performed per country (n = 5,543) and included: 1) construct
validity by item convergent and discriminant validity, 2) internal
consistency reliability by Cronbach’s alpha and 3) clinical valid-
ity by describing the scores according to ISR severity. RESULTS:
After item reduction, the ﬁnal questionnaire comprised 4 multi-
item dimensions (“bother”; “arm movement”; “sleep”; “accept-
ability”) grouping 16 items plus 5 individual items (anxiety
before vaccination; bother by pain during vaccination; satisfac-
tion with the injection system; anxiety of being vaccinated next
year; willingness to be vaccinated again). Item convergent and
discriminant validity was conﬁrmed for all scales in most coun-
tries. Multi-item dimension internal consistency reliability was
good to excellent for all countries (Cronbach’s alpha ranging
from 0.73 to 0.94), except for the “sleep” dimension in Italy
(0.68). Dimension scores demonstrated good clinical validity:
greater severity of ISR was associated with higher scores. CON-
CLUSION: The self-administered VAPI questionnaire is valid
and reliable. Therefore, it is a promising tool for the assessment
of the acceptance of a vaccine injection system.
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OBJECTIVES: Compare data from a large national EMR in the
US to national published data. METHODS: Data from GE
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Centricity are compared with national US data (NHANES,
NHIS, Kaiser Family Foundation and Census) including demo-
graphics and two common diseases, hypertension and diabetes.
Data from 2004 and 2005 are used for all comparisons. EMR
data is included for all patients with activity in 2005. ICD-9
codes were used to identify patients. FBG levels were used in
NHANES patients for diabetes. RESULTS: In total, 3,127,682
EMR patients were available; 2,644,181 of these were 18 and
older. EMR population was older than the general US popula-
tion. A percentage of EMR patients was lower in <18 and 18–44,
and higher in 45–64, 65–74, and 75+. EMR patients had pre-
dominantly commercial insurance (73.0%) and those with Med-
icaid were lower and Medicare higher than the US population.
Racial distribution was similar with EMR having a lower per-
centage of white patients (78.8%, 81.0%) and a higher percent-
age of black patients (13.5%, 12.7%). EMR patients were
overrepresented in the Northeast and Midwest and underrepre-
sented in the West and South and were predominantly female
(59.9%). A total of 683,936 hypertensive EMR patients were
identiﬁed (258.7/1000) as compared with 248.7/1000 (NHIS).
Prevalence of hypertension in EMR patients was higher in
males than females (286.6/1000 vs. 240.0/1000). Adult diabetic
patients were overrepresented in the EMR with 97.8/1000 vs
71.7/1000 (NHIS) and 58.6/1000 (NHANES (FPG > 125 mg/
dl)). CONCLUSION: EMR patients are older than the US popu-
lation and more likely to be female. Prevalence values were
similar for hypertension and higher in EMR patients for diabetes.
This may reﬂect the fact that the EMR is used primarily in
ambulatory primary care practices. EMR data is generally rep-
resentative of the US population but differences may exist
depending on the disease and population of interest.
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OBJECTIVES: The gap between “efﬁcacy” in clinical trials and
“effectiveness” in real practice due to patient selection, non-
compliance and treatment patterns has been broadly recognized
among health-care decision makers. However little attention has
been paid for statistical errors accompanied in clinical trials,
which may cause the gap. The purpose of this study is to develop
a new analytical framework to estimate the degree of the gap
caused by statistical errors. METHODS: The expected cost-
effectiveness ratio (QP) in the real world was formulated in terms
of a vector by using a decision analytic approach assuming an
evidence-based treatment choice from two treatment options: a
new treatment (TA) and a conventional treatment (TB). The
value of QP varies depending on the parameters such as cost-
effectiveness evidence of TA and TB, type  and type  errors,
and a Bayesian prior probability that TA is better than TB. The
prior probability is usually estimated by the following two steps:
1) Bayesian inference based on binomial modeling, and 2)
Normal approximation of the binomial modeling with the log
odds ratio. Then the derived prior probability was applied for
our formula to estimate the gap, called “gap formula”, by using
a hypothetical dataset. In addition, a Monte Carlo simulation
was performed as probabilistic sensitivity analysis. RESULTS:
Adaptive estimations of Bayes provided ﬂexible evaluation for
the gap formula between real world and clinical trials. The result
of the Monte Carlo simulations quantitatively illustrated with
distributions how much the QP could be deviated, mainly
depending on the type  error, from the ideal average cost-
effectiveness ratio. CONCLUSION: The series of methods we
developed can be applied in adaptive design for trial-based cost-
effectiveness analyses such as sample-size calculation considering
the inﬂuence of statistical errors.
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OBJECTIVES: In probabilistic sensitivity analysis of a cost-
effectiveness (CE) study, the unknown parameters, like transition
probabilities, are considered random variables. A crucial ques-
tion is what probabilistic distribution is suitable as synthesizing
the available information (mainly data from clinical trials) about
these parameters. In this context, it has been recognized the
important role of the Bayesian methodology, under which, the
parameters are of random nature.
Despite the great appealing of the Bayesian approach to proba-
bilistic sensitivity analysis, the “lack of objectivity” has been
frequently argued as the main issue precluding the adoption of
Bayesian techniques. This legitime concern has inspired the
development of formal objective priors over the last decades.
These priors are obtained as the result of mathematical formal
rules applied to the models at hand and lead to Bayesian analyses
inﬂuenced only by the data at hand. Formal objective priors have
a number of appealing properties, including excellent frequentist
behaviour.
We explore, in the context of CE analyses, how formal
objective Bayesian methods can be implemented. Speciﬁcally,
we consider two problems that frequently appear in the CE
literature: survival analysis and meta-analysis. We describe in
detail the numerical methods that needs to be used to obtain the
results.
The methodology is fully illustrated using two CE analysis
published in the literature. We compare our results with those
obtained with other approaches to probabilistic sensitivity analy-
sis. We conclude that the differences, when compared with other
approaches, can be quite quite marked, specially when the
number of patients enrolled in the simulated cohort under study
is large.
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OBJECTIVES: Probabilistic sensitivity analysis (PSA) of eco-
nomic evaluations has become more important because decision
makers want to know how uncertain results are. We evaluated
the consistency of PSA methods and how well they adhered
to published recommendations. METHODS: Publications of
methodological guidelines on the conduct of PSA were re-
viewed by three researchers, and a consensus set of criteria
for assessing PSAs were developed. English language health
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